Compare iShares China Large-Cap ETF (FXI) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Teladoc Health Inc — how do they compare? iShares China Large-Cap ETF trades at $34.55, while Teladoc Health Inc trades at $9.59 (market cap $1.75B). The key difference: Teladoc Health Inc is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals.
| FXI | TDOC | |
|---|---|---|
52-Week High | $41.75 | $9.72 |
52-Week Low | $31.59 | $4.47 |
Market Cap | — | $1.75B |
Sector | — | Health |
Enterprise Value | — | $2.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares China Large-Cap ETF (FXI) trades at $34.535, up 2.27% on the day, with technical indicators showing a bullish overall signal despite some overbought RSI readings. Recent news highlights China's significant push into AI and electric vehicles, including a reported $295 billion AI infrastructure plan and a 30% NEV fleet target by 2030, which could benefit the large-cap Chinese companies held within the fund.
The outlook for FXI is tied to China's economic policy execution and its success in strategic sectors like AI and EVs. Key opportunities include exposure to state-backed industrial and tech giants, while risks stem from U.S.-China tech rivalry, regulatory shifts, and the potential for Chinese equities to act as a value trap despite apparent undervaluation.
TDOC trades at $9.56, up 3.13% with bullish technical signals from moving averages. The company reported mixed Q1 2026 earnings, missing expectations with a -$0.36 EPS, but maintains strong revenue of $2.53B and a gross margin of 69.29%. Recent partnership expansions with Walmart highlight growth initiatives, though net losses persist at -$200.32M. Analyst consensus is mixed with 35.71% buy ratings but a price target below current levels at $8.75.
The outlook remains cautious due to ongoing net losses and negative cash flow trends, with net cash flow at -$517.24M in 2025. Key risks include competitive pressures and execution challenges, but cost-cutting and market expansion could support recovery. Investors should weigh the low P/S ratio of 0.69 against profitability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
